Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety
FORT LEE, N.J., July 29, 2025 /PRNewswire/ — Kedrion Biopharma is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Coagulation Factor X human (tradename COAGADEX) for the treatment of acquired Factor X Deficiency (aFXD), a rare hematologic disorder with a global prevalence of < 1








